In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone's ...

Gyre Therapeutics (GYRE) announced that the National Medical Products Administration, NMPA, of the People’s Republic of China, PRC, has ...

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated ...

Earnings per share (EPS) missed analyst estimates by 71%. In the last 12 months, the only revenue segment was Gyre Pharmaceuticals contributing US$105.8m. The largest operating expense was Sales ...

Gyre plans to submit an IND application in 2026. For the full year 2025, the Company expects to generate revenues of $118 to $128 million, representing growth of 11.3% to 20.8% over 2024 revenue ...